Literature DB >> 23479502

The role of angiogenesis in human non-Hodgkin lymphomas.

Domenico Ribatti1, Beatrice Nico, Girolamo Ranieri, Giorgina Specchia, Angelo Vacca.   

Abstract

The role of angiogenesis in the growth of lymphomas and survival of patients with leukemias and other hematological malignancies has become evident since 1994. Angiogenic factors, such as vascular endothelial growth factor and its receptors together with other tumor microenvironment components, including myelo-monocytic cell, mast cells, endothelial progenitor cells, and circulating endothelial cells, have been shown to be important in the progression and maintenance of lymphoproliferative disorders. In this review article, we present an overview of the literature focusing on the relationship between angiogenesis and disease progression and the recent advantages in the antiangiogenic treatment in human non-Hodgkin lymphomas.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23479502      PMCID： PMC3593147          DOI： 10.1593/neo.121962

Source DB:  PubMed          Journal:  Neoplasia        ISSN： 1476-5586            Impact factor:   5.715


  115 in total

1.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia.

Authors:  D Ribatti; S Molica; A Vacca; B Nico; E Crivellato; A M Roccaro; F Dammacco
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

3.  Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Laurie H Sehn; David MacDonald; Sheldon Rubin; Guy Cantin; Morel Rubinger; Bernard Lemieux; Sanraj Basi; Kevin Imrie; Randy D Gascoyne; Jonathan Sussman; Bingshu E Chen; Marina Djurfeldt; Lois Shepherd; Stephen Couban; Michael Crump
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

4.  Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.

Authors:  Nozomi Niitsu; Masataka Okamato; Hirokazu Nakamine; Tadashi Yoshino; Jun-ichi Tamaru; Shigeo Nakamura; Masaki Higashihara; Masami Hirano
Journal:  Eur J Haematol       Date:  2002-02       Impact factor: 2.997

5.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9.

Authors:  A Vacca; S Moretti; D Ribatti; A Pellegrino; N Pimpinelli; B Bianchi; E Bonifazi; R Ria; G Serio; F Dammacco
Journal:  Eur J Cancer       Date:  1997-09       Impact factor: 9.162

7.  Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.

Authors:  F Bertolini; L Fusetti; P Mancuso; A Gobbi; C Corsini; P F Ferrucci; G Martinelli; G Pruneri
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

8.  Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.

Authors:  Roberto Ria; Teresa Cirulli; Teresa Giannini; Santa Bambace; Gabriella Serio; Maurizio Portaluri; Domenico Ribatti; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

9.  Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways.

Authors:  W J Rettig; H P Erickson; A P Albino; P Garin-Chesa
Journal:  J Cell Sci       Date:  1994-02       Impact factor: 5.285

10.  Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane.

Authors:  Jürgen Becker; Ana Covelo-Fernandez; Frederike von Bonin; Dieter Kube; Jörg Wilting
Journal:  Vasc Cell       Date:  2012-03-09
View more
  29 in total

1.  The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.

Authors:  Jelena Jelicic; Milena Todorovic Balint; Maja Perunicic Jovanovic; Novica Boricic; Marjan Micev; Jelena Stojsic; Darko Antic; Bosko Andjelic; Jelena Bila; Bela Balint; Sonja Pavlovic; Biljana Mihaljevic
Journal:  Pathol Oncol Res       Date:  2016-01-11       Impact factor: 3.201

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.

Authors:  Bonnie Huang; Wuhbet D Abraham; Yiran Zheng; Sandra C Bustamante López; Samantha S Luo; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

4.  B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.

Authors:  Sara J McKee; Zewen K Tuong; Takumi Kobayashi; Brianna L Doff; Megan Sf Soon; Michael Nissen; Pui Yeng Lam; Colm Keane; Frank Vari; Davide Moi; Roberta Mazzieri; Graham Leggatt; Maher K Gandhi; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2017-12-18       Impact factor: 8.110

Review 5.  Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.

Authors:  Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Hironori Koga; Takato Ueno; Robert S Kerbel; Michio Sata
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

6.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

7.  Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.

Authors:  Shuyun Rao; Kathy Q Cai; Jason E Stadanlick; Noa Greenberg-Kushnir; Nehal Solanki-Patel; Sang-Yun Lee; Shawn P Fahl; Joseph R Testa; David L Wiest
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

8.  High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.

Authors:  Martin Mohren; Kathleen Jentsch-Ullrich; Michael Koenigsmann; Siegfried Kropf; Enrico Schalk; Gerd Lutze
Journal:  Int J Hematol       Date:  2015-11-26       Impact factor: 2.490

Review 9.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

10.  Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.

Authors:  H J Choi; J Y Kim; S-C Lim; G Kim; H J Yun; H S Choi
Journal:  Br J Pharmacol       Date:  2015-10-16       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.